<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5131">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169493</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00025144</org_study_id>
    <secondary_id>10CRP3630033</secondary_id>
    <nct_id>NCT01169493</nct_id>
  </id_info>
  <brief_title>Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)</brief_title>
  <acronym>PACE-RBBB</acronym>
  <official_title>Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) affects 5 million Americans and is responsible for more health-care
      expenditure than any other medical diagnosis. Approximately half of all HF patients have
      electrocardiographic prolongation of the QRS interval and ventricular dyssynchrony, a
      perturbation of the normal pattern of ventricular contraction that reduces the efficiency of
      ventricular work. Ventricular dyssynchrony is directly responsible for worsening HF
      symptomatology in this subset of patients. Resynchronization of ventricular contraction is
      usually achieved through simultaneous pacing of the left and right ventricles using a
      biventricular (BiV) pacemaker or implantable cardioverter-defibrillator. Clinical trial
      evidence supporting the use of BiV pacing in patients with prolonged QRS duration was
      obtained almost exclusively in patients with a left bundle-branch block (LBBB)
      electrocardiographic pattern. Recent evidence suggests that resynchronization of ventricular
      contraction in patients with LBBB can be obtained by univentricular left ventricular pacing
      with equal or superior clinical benefits compared to BiV pacing. Animal studies suggest that
      ventricular resynchronization can be obtained in subjects with right bundle-branch block
      (RBBB) through univentricular right ventricular pacing. No clinical trial evidence exists to
      support the use of BiV pacing in patients with RBBB. Thousands of patients with symptomatic
      HF and RBBB currently have univentricular ICDs in place for the prevention of sudden cardiac
      death. Most of these devices are currently programmed to avoid RV pacing. We aim to
      determine if ventricular resynchronization delivered through univentricular RV pacing
      improves symptoms in patients with RBBB and moderate to severe HF who have previously
      undergone BiV ICD implantation for symptomatic heart failure. We further aim to determine if
      ventricular resynchronization improves myocardial performance and ventricular geometry as
      detected by echocardiographic measures and quality of life for patients with HF and RBBB. We
      hypothesize that RV univentricular pacing delivered with an atrio-ventricular interval that
      maximizes ventricular synchrony is equivalent to BiV pacing for improvement in cardiac
      performance, HF symptoms, and positive ventricular remodeling in patients with HF and RBBB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of &gt;5mm.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Echocardiographic Endpoints</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparisons of the derived velocity-time integral calculated on the aortic continuous wave Doppler-spectrogram, comparisons of LV and RV end-diastolic size, LV and RV EF, mitral and tricuspid regurgitation severity, and estimated RV systolic pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints of the PACE-RBBB Trial Will Also Include Comparisons of NYHA Functional Class, 6-minute Walk Distance, and Minnesota Quality of Life Questionnaire Scores Between Treatment Groups.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmic Events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine if pacing mode impacts the frequency of ventricular arrhythmias, the incidence of ventricular tachyarrhythmia episodes on device interrogation will be compared between treatment group assignments. An episode will be considered ventricular arrhythmia if it lasts longer than 30 seconds or requires anti-tachycardia pacing or high voltage device therapy for termination.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Heart Failure</condition>
  <condition>Right Bundle-Branch Block</condition>
  <arm_group>
    <arm_group_label>VVI-40 to RV DDD-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VVI-40 to Bi-V DDD-40 to RV DDD-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bi-V DDD-40 to VVI-40 to RV DDD-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bi-V DDD-40 to RV DDD-40 to VVI-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV DDD-40 to VVI-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV DDD-40 to Bi-V DDD-40 to VVI-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VVI-40</intervention_name>
    <description>Pacing mode set to VVI-40, RV only pacing</description>
    <arm_group_label>VVI-40 to RV DDD-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>VVI-40 to Bi-V DDD-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to VVI-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to RV DDD-40 to VVI-40</arm_group_label>
    <arm_group_label>RV DDD-40 to VVI-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>RV DDD-40 to Bi-V DDD-40 to VVI-40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RV DDD-40</intervention_name>
    <description>ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.</description>
    <arm_group_label>VVI-40 to RV DDD-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>VVI-40 to Bi-V DDD-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to VVI-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to RV DDD-40 to VVI-40</arm_group_label>
    <arm_group_label>RV DDD-40 to VVI-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>RV DDD-40 to Bi-V DDD-40 to VVI-40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiV DDD-40</intervention_name>
    <description>ICD programmed to BiV pacing at a lower rate of 40</description>
    <arm_group_label>VVI-40 to RV DDD-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>VVI-40 to Bi-V DDD-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to VVI-40 to RV DDD-40</arm_group_label>
    <arm_group_label>Bi-V DDD-40 to RV DDD-40 to VVI-40</arm_group_label>
    <arm_group_label>RV DDD-40 to VVI-40 to Bi-V DDD-40</arm_group_label>
    <arm_group_label>RV DDD-40 to Bi-V DDD-40 to VVI-40</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiomyopathy of either idiopathic or ischemic etiology

          -  NYHA class III, or IV symptoms

          -  Sinus rhythm

          -  QRS complex duration &gt; 130 msec in ≥ 2 surface ECG leads with RBBB

          -  PR interval &gt; 150 msec and &lt; 240 msec

          -  Prior implantation of dual chamber BiV ICD with apical RV lead location

        Exclusion Criteria:

          -  Myocardial infarction, major surgical procedure, or acute cardiac failure crisis
             requiring inotropes within 6 months of entry into the study

          -  Atrial fibrillation or flutter lasting &gt;12 hours within the last 6 months

          -  Sick sinus syndrome, complete heart block, or other arrhythmias requiring pacemaker
             support

          -  Pregnancy

          -  Any other known condition other than heart failure that could limit exercise time or
             survival to &lt; 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett D Atwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 28, 2015</lastchanged_date>
  <firstreceived_date>July 22, 2010</firstreceived_date>
  <firstreceived_results_date>August 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Right Bundle-Branch Block</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bundle-Branch Block</mesh_term>
    <mesh_term>Heart Block</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VVI-40 to RV DDD-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2.
Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3.
Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="P2">
          <title>VVI-40 to Bi-V DDD-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2.
Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3.
Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="P3">
          <title>Bi-V DDD-40 to VVI-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2.
Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3.
Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="P4">
          <title>Bi-V DDD-40 to RV DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="P5">
          <title>RV DDD-40 to VVI-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="P6">
          <title>RV DDD-40 to Bi-V DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VVI-40 to RV DDD-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B2">
          <title>VVI-40 to Bi-V DDD-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B3">
          <title>Bi-V DDD-40 to VVI-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B4">
          <title>Bi-V DDD-40 to RV DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B5">
          <title>RV DDD-40 to VVI-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B6">
          <title>RV DDD-40 to Bi-V DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="5"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6"/>
                <measurement group_id="B7" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4"/>
                <measurement group_id="B5" value="3"/>
                <measurement group_id="B6"/>
                <measurement group_id="B7" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4"/>
                <measurement group_id="B5" value="5"/>
                <measurement group_id="B6"/>
                <measurement group_id="B7" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of &gt;5mm.</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who completed the six month period for VVI-40, RV DDD-40, Bi-V DDD-40 regardless of which arm they are randomized to. Participants may be counted as completing more than one period.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI-40</title>
            <description>The VVI-40 arm will be programmed to VVI (inhibited) mode at a lower rate of 40.</description>
          </group>
          <group group_id="O2">
            <title>RV DDD-40</title>
            <description>RV DDD-40 will have an AV interval set to produce QRS fusion with the native conduction down the native left bundle</description>
          </group>
          <group group_id="O3">
            <title>Bi-V DDD-40</title>
            <description>Permits direct comparison of RV univentricular pacing and current standard of care (BiV) pacing.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of &gt;5mm.</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Echocardiographic Endpoints</title>
        <description>Comparisons of the derived velocity-time integral calculated on the aortic continuous wave Doppler-spectrogram, comparisons of LV and RV end-diastolic size, LV and RV EF, mitral and tricuspid regurgitation severity, and estimated RV systolic pressure.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoints of the PACE-RBBB Trial Will Also Include Comparisons of NYHA Functional Class, 6-minute Walk Distance, and Minnesota Quality of Life Questionnaire Scores Between Treatment Groups.</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arrhythmic Events</title>
        <description>To determine if pacing mode impacts the frequency of ventricular arrhythmias, the incidence of ventricular tachyarrhythmia episodes on device interrogation will be compared between treatment group assignments. An episode will be considered ventricular arrhythmia if it lasts longer than 30 seconds or requires anti-tachycardia pacing or high voltage device therapy for termination.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VVI-40 to RV DDD-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="E2">
          <title>VVI-40 to Bi-V DDD-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="E3">
          <title>Bi-V DDD-40 to VVI-40 to RV DDD-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="E4">
          <title>Bi-V DDD-40 to RV DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="E5">
          <title>RV DDD-40 to VVI-40 to Bi-V DDD-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
        <group group_id="E6">
          <title>RV DDD-40 to Bi-V DDD-40 to VVI-40</title>
          <description>Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
VVI-40: Pacing mode set to VVI-40, RV only pacing
RV DDD-40: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
BiV DDD-40: ICD programmed to BiV pacing at a lower rate of 40</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure Exacerbation, Heart Transplant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We were unable to enroll adequately, and the study was underpowered to assess either the safety or efficacy of RV only, or BIV pacing in patients with right bundle branch block.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Brett D. Atwater, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>9196848111</phone>
      <email>brett.atwater@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
